搜索
Xencor Inc
XNCR添加自选
14.924USD
-0.456-2.96%
收盘 07/02, 13:00（美东）报价延迟15分钟
1.11B总市值
亏损市盈率 TTM
关键数据
15.390今开
15.720最高
410.68K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.55%换手率
15.380昨收
14.890最低
4.07M成交额
亏损市盈率静
2.14市净率
0.00%股息率 TTM
-21.01%ROA
18.69052周最高
0.64量比
-232.62M净利润
74.06M总股本
-2.2942每股收益TTM
0.92Beta
-29.84%ROE
6.92052周最低
5.40%振幅
100.00%毛利率
1.11B总市值
10.12回报/风险
3.68%风险率
TradingKey Xencor Inc股票评分
单位: USD 更新时间: 2026-07-01操作建议
Xencor Inc当前公司基本面数据相对稳定，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名73/387位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价29.82。中期看，股价处于上升通道。近一个月，市场表现很强，技术面评分较高，但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Xencor Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Xencor Inc亮点
亮点风险
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
估值合理
公司最新PE估值-6.70，处于3年历史合理位
分析师目标
根据
14
位分析师
买入
评级
29.818
目标均价
+85.21%
涨幅空间
Xencor Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Xencor Inc简介
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
公司代码XNCR
公司Xencor Inc
CEODahiyat (Bassil I)
网址https://xencor.com/
相关品种
热门品种
常见问题
Xencor Inc(XNCR)的当前股价是多少？
Xencor Inc(XNCR)的当前股价是 15.38。
Xencor Inc的股票代码是什么？
Xencor Inc的股票代码是XNCR。
Xencor Inc股票的52周最高点是多少？
Xencor Inc股票的52周最高点是18.69。
Xencor Inc股票的52周最低点是多少？
Xencor Inc股票的52周最低点是6.92。
Xencor Inc的市值是多少？
Xencor Inc的市值是1.14B。
现在Xencor Inc(XNCR)的股票是买入、持有还是卖出？
根据分析师评级，Xencor Inc(XNCR)的总体评级为买入，目标价格为29.82。
Xencor Inc(XNCR)股票的每股收益（EPS TTM）是多少
Xencor Inc(XNCR)股票的每股收益（EPS TTM）是-1.24。